Key result
In patients with acute coronary syndrome undergoing PCI, cardiovascular death occurred in 2% of patients on prasugrel or ticagrelor compared to 3% on clopidogrel, with no statistically significant difference (p=0.9025).
Why the study?
Does the choice of P2Y12 inhibitor (prasugrel or ticagrelor vs clopidogrel) improve cardiovascular outcomes and affect bleeding in patients with ACS undergoing PCI?
Observational (n=200)
No
Does the choice of P2Y12 inhibitor (prasugrel or ticagrelor vs clopidogrel) improve cardiovascular outcomes and affect bleeding in patients with ACS undergoing PCI?
Absolute Event Rate: 2% vs 3%
p-value: p=0.9025
No takes yet. Share an insight, caveat, or question.
Observational data link clopidogrel to more ischemic events than prasugrel or ticagrelor; leaves open optimal P2Y12 selection pending RCTs.
Passi et al. (2017) conducted an observational in Acute Coronary Syndrome (n=200). Prasugrel or Ticagrelor vs. Clopidogrel was evaluated on Cardiovascular death (p=0.9025). In patients with acute coronary syndrome undergoing PCI, cardiovascular death occurred in 2% of patients on prasugrel or ticagrelor compared to 3% on clopidogrel, with no statistically significant difference (p=0.9025).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: